(Total Views: 271)
Posted On: 08/22/2020 10:20:35 AM
Post# of 36566
Doc, I might not be able to join the call or I might have to leave it, I have a video call with my Cardiologist as well, so here are my questions.
1). Are there any tangible sales figures from any of the acquisitions and products that Generex currently has?
2). Can we get a synopsis of what should be achieved within the next 30, 60, 90 days, instead of what can be achieved when funding occurs down the road. What can they do in those timeframes now, so shareholders know what is going on now.
3). Have they been in any discussions themselves with the SEC on status of S-1 for Generex and Form 10 for NGIO and for NGIO, when can S-1 be expected (timeframe)?
4). Have they had companies / anyone looking into possibly buying pieces of Generex, such as excellagon, or AE37?
1). Are there any tangible sales figures from any of the acquisitions and products that Generex currently has?
2). Can we get a synopsis of what should be achieved within the next 30, 60, 90 days, instead of what can be achieved when funding occurs down the road. What can they do in those timeframes now, so shareholders know what is going on now.
3). Have they been in any discussions themselves with the SEC on status of S-1 for Generex and Form 10 for NGIO and for NGIO, when can S-1 be expected (timeframe)?
4). Have they had companies / anyone looking into possibly buying pieces of Generex, such as excellagon, or AE37?
(0)
(0)
